Johnson Pharmacare (532154) Q4 15/16 earnings summary

Executive summary

• No business activity or operating revenue in FY2015-16; administrative expenses drove a net loss of ₹1,255,927.

• Operations were constrained by scarce working capital; management pursued cost reductions and sought an opportunity to restart activity.

Financial highlights

• Revenue from operations and other income were nil; total expenses were ₹1,255,927, versus ₹737,735 in FY2014-15.

• Net loss was ₹1,255,927, compared with ₹737,735 in FY2014-15; administrative expenses were ₹1,132,447, including ₹531,000 in professional fees.

• Cash and cash equivalents closed at ₹3,351,029, up from ₹2,712,108; operating cash flow was negative ₹109,419,673.

Outlook and guidance

• Future development depends on resuming operations; management was pursuing opportunities and implementing feasible cost reductions.

• Forward-looking expectations carry uncertainty, with actual results potentially differing materially from projections and estimates.